리메드

302550KOSDAQ의료용 기기 제조업

48.3 / 100

Reference Date: 2026-06-10

Financial Score10.5 / 40

News Sentiment18.8 / 25

Momentum5.0 / 20

Disclosure14.0 / 15

AI Analysis: ROE is below the industry average, PER raises overvaluation concerns. Declined 5.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Remed is a company specializing in developing and manufacturing medical devices that utilize non-invasive magnetic stimulation technology to treat various conditions such as depression, stroke, and chronic pain. Its key products, BrainStim and ALTMS, have received FDA and KFDA certifications for depression treatment and are expanding globally. The company also offers chronic pain management through NMS and aesthetic services via CSMS.

Number of Employees

114people

Average Salary

46.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

164.12Industry Average 21.510.0Point

7.6x industry avg (risky)

PBR

2.19Industry Average 1.381.0Point

1.6x industry avg (risky)

ROE

-0.09Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

12.60Industry Average 11.652.0Point

Higher than industry avg (caution)

Trend 2023~20257.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲16.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲52.0% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.2% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
리메드, 20억 규모 자사주 취득 신탁계약 체결 결정
리메드의 자사주 취득 신탁계약 체결로 주주가치 제고 기대

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 2,790Won52-week high 3,98552-week low 2,730

1-month return2.0Point

1m -5.42% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 2Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-05-28
Positive주요사항보고서(자기주식취득신탁계약체결결정)2026-05-20
Positive주요사항보고서(자기주식취득신탁계약해지결정)2026-05-20
Neutral신탁계약해지결과보고서2026-05-20
Neutral분기보고서 (2026.03)2026-05-14